免疫检查点抑制剂治疗非小细胞肺癌的研究现状和前景
Research Status and Prospect of Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer
DOI: 10.12677/ACM.2023.1381762, PDF,    科研立项经费支持
作者: 于楠楠, 赵 红*：延安大学附属医院肿瘤科，陕西 延安
关键词: 非小细胞肺癌；免疫治疗；PD-L1抑制剂；免疫检查点抑制剂；Non-Small Cell Lung Cancer； Immunotherapy； PD-L1 Inhibitors； Immune Checkpoint Inhibitors
摘要: 非小细胞肺癌(non-small cell lung cancer, NSCLC)是肺癌的主要病理类型，大部分患者就医时已是晚期，其5年生存率约仅为15%。现阶段以免疫检查点抑制剂(Immune checkpoint inhibitor, ICI)作为代表的免疫治疗时代的到来为肺癌领域带来了革命性的突破，显著延长了肺癌患者的生存时间，已经成为非小细胞肺癌患者不可或缺的治疗手段。肺癌免疫治疗取得新突破的同时，免疫检查点抑制剂在肺癌治疗领域也有了更深层次的研究，因此，本文总结了不同时期非小细胞肺癌免疫检查点抑制剂治疗的研究现状，探讨了现阶段需应对的挑战，并指出了未来的研究前景。
Abstract: Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, most patients with NSCLC are in advanced stage when they seek medical treatment, and their 5-year survival rate is only about 15%. The advent of the era of immunotherapy represented by immune checkpoint in-hibitor (ICI) has brought a revolutionary breakthrough in the field of lung cancer, significantly ex-tending the survival time of lung cancer patients, and has become an indispensable treatment for non-small cell lung cancer patients. With new breakthroughs in lung cancer immunotherapy, im-mune checkpoint inhibitors have also been further studied in the field of lung cancer treatment. Therefore, this review summarizes the research status of immune checkpoint inhibitors for NSCLC in different periods, discusses the challenges to be met at present, and points out the future re-search prospects.
文章引用：于楠楠, 赵红. 免疫检查点抑制剂治疗非小细胞肺癌的研究现状和前景[J]. 临床医学进展, 2023, 13(8): 12559-12570. https://doi.org/10.12677/ACM.2023.1381762

参考文献

[1] Barta, J.A., Powell, C.A. and Wisnivesky, J.P. (2019) Global Epidemiology of Lung Cancer. Annals of Global Health, 85, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[2] Cao, W., Chen, H.-D., Yu, Y.-W., Li, N. and Chen, W.-Q. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal, 134, 783-791. [Google Scholar] [CrossRef] 
[3] Alexander, M., Kim, S.Y. and Cheng, H. (2020) Update 2020: Management of Non-Small Cell Lung Cancer. Lung, 198, 897-907. [Google Scholar] [CrossRef] [PubMed]
[4] Tocheva, A.S. and Mor, A. (2017) Checkpoint Inhibitors: Ap-plications for Autoimmunity. Current Allergy and Asthma Reports, 17, Article No. 72. [Google Scholar] [CrossRef] [PubMed]
[5] Mamdani, H., Matosevic, S., Khalid, A.B., Durm, G. and Jalal, S.I. (2022) Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Frontiers in Immunology, 13, Article 823618. [Google Scholar] [CrossRef] [PubMed]
[6] 陈思, 赵泽锐, 龙浩. 新辅助免疫治疗及联合化疗在NSCLC中的研究进展[J]. 中国肺癌杂志, 2021, 24(4): 284-292.
[7] Jiang, J., Wang, Y., Gao, Y., et al. (2022) Neoadjuvant Immunotherapy or Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Translational Lung Cancer Research, 11, 277-294. [Google Scholar] [CrossRef] [PubMed]
[8] Forde, P.M., Chaft, J.E., Smith, K.N., et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 378, 1976-1986. [Google Scholar] [CrossRef] 
[9] Lee, J., Chaft, J., Nicholas, A., et al. (2019) P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial. Journal of Thoracic Oncology, 14, S744. [Google Scholar] [CrossRef] 
[10] Tao, X., Li, N., Wu, N., et al. (2020) The Efficiency of 18F-FDG PET-CT for Predicting the Major Pathologic Response to the Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. European Journal of Nuclear Medicine and Molecular Imaging, 47, 1209-1219. [Google Scholar] [CrossRef] [PubMed]
[11] Cascone, T., William Jr., W.N., Weissferdt, A., et al. (2021) Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Ran-domized NEOSTAR Trial. Nature Medicine, 27, 504-514. [Google Scholar] [CrossRef] [PubMed]
[12] Provencio, M., Nadal, E., Insa, A., et al. (2020) Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Sin-gle-Arm, Phase 2 Trial. The Lancet Oncology, 21, 1413-1422. [Google Scholar] [CrossRef] 
[13] Forde, P.M., Spicer, J., Lu, S., et al. (2022) Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 386, 1973-1985. [Google Scholar] [CrossRef] 
[14] Kenmotsu, H., Sugawara, S., Watanabe, Y., et al. (2022) Adjuvant Atezolizumab in Japanese Patients with Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010). Cancer Science, 113, 4327-4338. [Google Scholar] [CrossRef] [PubMed]
[15] Antonia, S.J., Villegas, A., Daniel, D., et al. (2017) Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. New England Journal of Medicine, 377, 1919-1929. [Google Scholar] [CrossRef] 
[16] Antonia, S.J., Villegas, A., Daniel D., et al. (2018) Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine, 379, 2342-2350. [Google Scholar] [CrossRef] 
[17] Spigel, D.R., Faivre-Finn, C., Gray, J.E., et al. (2022) Five-Year Survival Outcomes from the PACIFIC Trial: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 1301-1311. [Google Scholar] [CrossRef] 
[18] Zhou, Q., Chen, M., Wu, G., et al. (2020) GEMSTONE-301: A Phase III Clinical Trial of CS1001 as Consolidation Therapy in Patients with Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer (NSCLC) Who Did Not Have Disease Progression after Prior Concurrent/Sequential Chemoradiotherapy. Translational Lung Cancer Research, 9, 2008-2015. [Google Scholar] [CrossRef] [PubMed]
[19] Jabbour, S.K., Lee, K.H., Frost, N., et al. (2021) Pembrolizumab plus Concurrent Chemoradiation Therapy in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncology, 7, 1351-1359. [Google Scholar] [CrossRef] [PubMed]
[20] Augustyn, A., Adams, D.L., He, J., et al. (2021) Giant Circulat-ing Cancer-Associated Macrophage-Like Cells Are Associated with Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated with Chemoradiation and Atezolizumab. Clinical Lung Cancer, 22, e451-e465. [Google Scholar] [CrossRef] [PubMed]
[21] 虞思来, 倪建佼, 朱正飞. 免疫治疗时代不可手术局部晚期非小细胞肺癌的治疗: 现状与展望[J]. 中国癌症杂志, 2022, 32(6): 487-498. [Google Scholar] [CrossRef] 
[22] Jabbour, S.K., Cho, B.C., Bria, E., et al. (2022) Ra-tionale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Fol-lowed by Pembrolizumab with or without Olaparib for Stage III Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 23, e342-e346. [Google Scholar] [CrossRef] [PubMed]
[23] De Ruysscher, D., Ramalingam, S., Urbanic, J., et al. (2022) CheckMate 73L: A Phase 3 Study Comparing Nivolumab plus Concurrent Chemoradiotherapy Followed by Nivolumab with or without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 23, e264-e268. [Google Scholar] [CrossRef] [PubMed]
[24] 高鸣, 周清, 吴一龙. 免疫时代下不可手术Ⅲ期非小细胞肺癌治疗变革[J]. 循证医学, 2022, 22(1): 23-29. [Google Scholar] [CrossRef] 
[25] Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2021) Five-Year Outcomes with Pembrolizumab versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, 39, 2339-2349. [Google Scholar] [CrossRef] 
[26] Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2019) Updated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. [Google Scholar] [CrossRef] 
[27] Mok, T.S.K., Wu, Y.-L., Kudaba, I., et al. (2019) Pembrolizumab ver-sus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. Lancet, 393, 1819-1830. [Google Scholar] [CrossRef] 
[28] Herbst, R.S., Giaccone, G., De Marinis, F., et al. (2020) Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. New England Journal of Medicine, 383, 1328-1339. [Google Scholar] [CrossRef] 
[29] Liu, G., Kang, S., Wang, X. and Shang, F. (2021) Cost-Effectiveness Analysis of Atezolizumab versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer with Different PD-L1 Expression Status. Frontiers in Oncology, 11, Article 669195. [Google Scholar] [CrossRef] [PubMed]
[30] Gogishvili, M., Melkadze, T., Makharadze, T., et al. (2022) Cemi-plimab plus Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Randomized, Controlled, Double-Blind Phase 3 Trial. Nature Medicine, 28, 2374-2380. [Google Scholar] [CrossRef] [PubMed]
[31] Xu, C.-R., Chen, Q., Zhou, C., et al. (2023) Effectiveness and Safety of Camrelizumab in Inoperable or Advanced Non-Small Cell Lung Cancer Patients: A Multicenter Real-World Retrospective Observational Study (CTONG2004-ADV). Translational Lung Cancer Research, 12, 127-140. [Google Scholar] [CrossRef] [PubMed]
[32] Gandhi, L., Rodriguez-Abreu, D., Gadgeel, S., et al. (2018) Pembroli-zumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine, 378, 2078-2092. [Google Scholar] [CrossRef] 
[33] Zhou, C., Chen, G., Huang, Y., et al. (2021) Camrelizumab plus Carboplatin and Pemetrexed versus Chemotherapy Alone in Chemotherapy-Naive Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (CameL): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Respiratory Medicine, 9, 305-314. [Google Scholar] [CrossRef] 
[34] Yang, Y., Wang, Z., Fang, J., et al. (2020) Efficacy and Safety of Sintilimab plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (Oncology Program by InnovENT Anti-PD-1-11). Journal of Thoracic Oncology, 15, 1636-1646. [Google Scholar] [CrossRef] [PubMed]
[35] Lu, S., Wang, J., Yu, Y., et al. (2021) Tislelizumab plus Chemo-therapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. Journal of Thoracic Oncology, 16, 1512-1522. [Google Scholar] [CrossRef] [PubMed]
[36] Li, W. and Wan, L. (2022) Cost-Effectiveness Analysis of Sugemalimab vs. Placebo, in Combination with Chemotherapy, for Treatment of First-Line Metastatic NSCLC in China. Frontiers in Public Health, 10, Article 1015702. [Google Scholar] [CrossRef] [PubMed]
[37] Ren, S., Chen, J., Xu, X., et al. (2022) Camrelizumab plus Car-boplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial. Journal of Thoracic Oncology, 17, 544-557. [Google Scholar] [CrossRef] [PubMed]
[38] West, H., Mccleod, M., Hussein, M., et al. (2019) Atezolizumab in Combination with Carboplatin plus Nab-Paclitaxel Chemotherapy Compared with Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non- Small-Cell Lung Cancer (Impower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 924-937. [Google Scholar] [CrossRef] 
[39] Paz-Ares, L., Luft, A., Vicente, D., et al. (2018) Pembroli-zumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 379, 2040-2051. [Google Scholar] [CrossRef] 
[40] Wang, J., Lu, S., Yu, X., et al. (2021) Tislelizumab plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncology, 7, 709-717. [Google Scholar] [CrossRef] [PubMed]
[41] Zhou, C., Wu, L., Fan, Y., et al. (2021) Sintilimab plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results from a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). Journal of Thoracic Oncology, 16, 1501-1511. [Google Scholar] [CrossRef] [PubMed]
[42] Hellmann, M.D., Paz-Ares, L., Bernabe Caro, R., et al. (2019) Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine, 381, 2020-2031. [Google Scholar] [CrossRef] 
[43] Brahmer, J.R., Lee, J.-S., Ciuleanu, T.-E., et al. (2023) Five-Year Survival Outcomes with Nivolumab plus Ipilimumab versus Chemotherapy as First-Line Treatment for Meta-static Non-Small-Cell Lung Cancer in CheckMate 227. Journal of Clinical Oncology, 41, 1200-1212. [Google Scholar] [CrossRef] 
[44] Paz-Ares, L., Ciuleanu, T-E., Cobo, M., et al. (2021) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Patients with Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 198-211. [Google Scholar] [CrossRef] 
[45] Liang, H. and Wang, M. (2019) Prospect of Immunotherapy Combined with Anti-Angiogenic Agents in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Management and Research, 11, 7707-7719. [Google Scholar] [CrossRef] 
[46] Huang, Y., Kim, B.Y.S., Chan, C.K., et al. (2018) Improving Im-mune-Vascular Crosstalk for Cancer Immunotherapy. Nature Reviews Immunology, 18, 195-203. [Google Scholar] [CrossRef] [PubMed]
[47] Socinski, M.A., Jotte, R.M., Cappuzzo, F., et al. (2018) Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. New England Journal of Medicine, 378, 2288-2301. [Google Scholar] [CrossRef] 
[48] Chen, S., Wu, Z., Shi, F., et al. (2022) Lenvatinib plus TACE with or without Pembrolizumab for the Treatment of Initially Unresectable Hepatocellular Carcinoma Harbouring Pd-L1 Ex-pression: A Retrospective Study. Journal of Cancer Research and Clinical Oncology, 148, 2115-2125. [Google Scholar] [CrossRef] [PubMed]
[49] 董琳, 刘欣, 鲁海玲. 晚期非小细胞肺癌抗血管生成治疗联合免疫检查点抑制剂的研究进展[J]. 实用肿瘤学杂志, 2022, 36(4): 351-355. [Google Scholar] [CrossRef] 
[50] Ren, S., He, J., Fang, Y., et al. (2022) Camrelizumab plus Apatinib in Treatment-Naive Patients with Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Sin-gle-Arm, Phase 2 Trial. Clinical and Research Reports, 3, Article ID: 100312. [Google Scholar] [CrossRef] [PubMed]
[51] 崔广华, 杨宇. 安罗替尼在晚期恶性肿瘤治疗中的研究进展[J]. 现代肿瘤医学, 2022, 30(16): 3032-3036. [Google Scholar] [CrossRef] 
[52] Maruhashi, T., Sugiura, D., Okazaki, I.M. and Okazaki, T. (2020) LAG-3: From Molecular Functions to Clinical Applications. Journal for ImmunoTherapy of Cancer, 8, e001014. [Google Scholar] [CrossRef] [PubMed]
[53] Zhao, B.-W., Zhang, F.-Y., Wang, Y., et al. (2022) LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials. Cancers, 14, Article No. 4975. [Google Scholar] [CrossRef] [PubMed]
[54] 苏春霞, 周彩存. 晚期非小细胞肺癌免疫治疗现状及未来方向[J]. 中国癌症杂志, 2022, 32(6): 478-486. [Google Scholar] [CrossRef] 
[55] Chauvin, J.-M. and Zarour, H.M. (2020) TIGIT in Cancer Immunotherapy. Journal for ImmunoTherapy of Cancer, 8, e000957. [Google Scholar] [CrossRef] [PubMed]
[56] Brazel, D., Ou, S.I. and Nagasaka, M. (2023) Tiragolumab (An-ti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer: Targets and Therapy, 14, 1-9. [Google Scholar] [CrossRef] 
[57] Marin-Acevedo, J.A., Kimbrough, E.O. and Lou, Y. (2021) Next Generation of Immune Checkpoint Inhibitors and beyond. Journal of Hematology & Oncology, 14, Article No. 45. [Google Scholar] [CrossRef] [PubMed]
[58] Qu, J., Mei, Q., Chen, L. and Zhou, J. (2020) Chimeric Antigen Receptor (CAR)-T-Cell Therapy in Non-Small-Cell Lung Cancer (NSCLC): Current Status and Future Perspectives. Cancer Immunology, Immunotherapy, 70, 619-631. [Google Scholar] [CrossRef] [PubMed]
[59] Yilmaz, A., Cui, H., Caligiuri, M.A. and Yu, J. (2020) Chimeric Antigen Receptor-Engineered Natural Killer Cells for Cancer Immunotherapy. Journal of Hematology & Oncology, 13, Article No. 168. [Google Scholar] [CrossRef] [PubMed]
[60] Hemminki, O., Dos Santos, J.M. and Hemminki, A. (2020) Oncolytic Viruses for Cancer Immunotherapy. Journal of Hematology & Oncology, 13, Article No. 84. [Google Scholar] [CrossRef] [PubMed]
[61] Schlom, J., Hodge, J.W., Palena, C., et al. (2014) Therapeutic Cancer Vaccines. In: Tew, K.D. and Fisher, P.B., Eds., Advances in Cancer Research, Vol. 121, Elsevier, Amsterdam, 67-124. [Google Scholar] [CrossRef] 
[62] Saxena, M., Van Der Burg, S.H., Melief, C.J.M. and Bhardwaj, N. (2021) Therapeutic Cancer Vaccines. Nature Reviews Cancer, 21, 360-378. [Google Scholar] [CrossRef] [PubMed]
[63] Saavedra, D., Neninger, E., Rodriguez, C., et al. (2018) CIMA-vax-EGF: Toward Long-Term Survival of Advanced NSCLC. Seminars in Oncology, 45, 34-40. [Google Scholar] [CrossRef] [PubMed]

为你推荐